The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SYRE | -24.85% | -90% | -36.87% | -92% |
| S&P | +13.19% | +87.83% | +13.42% | +229% |
Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $1.01B | -32.4% |
| Market Cap / Employee | $10.66M | -78.7% |
| Employees | 95 | 0.0% |
| Net Income | -$11.18M | 79.2% |
| EBITDA | -$56.89M | -2.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $64.90M | -9.3% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -27.58% | -51.1% |
| Return On Invested Capital | -69.72% | 36.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$37.12M | -25.8% |
| Operating Free Cash Flow | -$37.12M | -25.8% |
| Metric | Q2 2024 | Q3 2024 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 25.42 | 3.19 | - | ||
| Price to Book | 6.97 | 2.69 | 2.76 | 2.23 | -67.32% |
| Price to Sales | 379.10 | 2012.97 | - | ||
| Price to Tangible Book Value | 6.97 | 2.69 | 2.76 | 2.23 | -67.32% |
| Enterprise Value to EBITDA | -13.70 | -10.52 | -7.36 | -9.36 | -58.13% |
| Return on Equity | -42.9% | -50.5% | -41.0% | -32.6% | -118.11% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
